{"title":"TGF-B-induced Cancer-associated Fibroblast Activation Promotes Tumor Progression In Oral Squamous Cell Carcinoma Mouse Model.","authors":"Junya Hirota, Daisuke Takeda, Yasuaki Sadakane, Yudai Matsuzoe, Yoshiaki Tadokoro, Aki Murakami, Nanae Yatagai, Izumi Saito, Masaya Akashi, Takumi Hasegawa","doi":"10.21873/anticanres.17731","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Oral squamous cell carcinoma (OSCC) is a common malignancy with a poor prognosis, partly due to interactions within the tumor microenvironment. Cancer-associated fibroblasts (CAFs), key stromal components, promote tumor progression by enhancing cancer cell migration, angiogenesis, and extracellular matrix remodeling. Transforming growth factor-beta (TGF-β) is known to induce CAF differentiation from normal fibroblasts (NFs), but its functional contribution in OSCC remains to be fully elucidated. This study explored the role of TGF-β in inducing the transition of NFs into CAFs and its impact on progression of OSCC.</p><p><strong>Materials and methods: </strong><i>In vitro</i>, NFs were treated with TGF-β, and CAF induction was assessed by evaluating the expression of the CAF marker α-smooth muscle actin (α-SMA) using quantitative real-time PCR and fluorescent immunostaining. OSCC cell migration was analyzed using a scratch assay. <i>In vivo</i>, TGF-β-treated or untreated NFs were co-injected with OSCC cells. The tumor size and VEGF, MMP2, and MMP9 expression were analyzed <i>via</i> quantitative real-time PCR and immunohistochemistry.</p><p><strong>Results: </strong><i>In vitro</i>, TGF-β-treated NFs exhibited significantly increased α-SMA expression and enhanced the OSCC migratory ability. <i>In vivo</i>, the TGF-β-treated group demonstrated a marked increase in tumor growth and up-regulated expression of VEGF, MMP2, and MMP9 compared to the untreated group.</p><p><strong>Conclusion: </strong>These findings suggest that TGF-β induces CAF differentiation and facilitates tumor progression by promoting angiogenesis and extracellular matrix degradation. This study highlights the potential of targeting TGF-β as a therapeutic strategy and underscores the need for novel approaches to counteract the tumor-promoting effects of CAFs.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3687-3700"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17731","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: Oral squamous cell carcinoma (OSCC) is a common malignancy with a poor prognosis, partly due to interactions within the tumor microenvironment. Cancer-associated fibroblasts (CAFs), key stromal components, promote tumor progression by enhancing cancer cell migration, angiogenesis, and extracellular matrix remodeling. Transforming growth factor-beta (TGF-β) is known to induce CAF differentiation from normal fibroblasts (NFs), but its functional contribution in OSCC remains to be fully elucidated. This study explored the role of TGF-β in inducing the transition of NFs into CAFs and its impact on progression of OSCC.
Materials and methods: In vitro, NFs were treated with TGF-β, and CAF induction was assessed by evaluating the expression of the CAF marker α-smooth muscle actin (α-SMA) using quantitative real-time PCR and fluorescent immunostaining. OSCC cell migration was analyzed using a scratch assay. In vivo, TGF-β-treated or untreated NFs were co-injected with OSCC cells. The tumor size and VEGF, MMP2, and MMP9 expression were analyzed via quantitative real-time PCR and immunohistochemistry.
Results: In vitro, TGF-β-treated NFs exhibited significantly increased α-SMA expression and enhanced the OSCC migratory ability. In vivo, the TGF-β-treated group demonstrated a marked increase in tumor growth and up-regulated expression of VEGF, MMP2, and MMP9 compared to the untreated group.
Conclusion: These findings suggest that TGF-β induces CAF differentiation and facilitates tumor progression by promoting angiogenesis and extracellular matrix degradation. This study highlights the potential of targeting TGF-β as a therapeutic strategy and underscores the need for novel approaches to counteract the tumor-promoting effects of CAFs.
期刊介绍:
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed.
ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.